Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC42 | P60953 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 6/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.42 |
| ▸ | WNT1 | P04628 | 4/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5449921 | 0.90 | CDC42 (0.80) | CDC42GAACASP6PRMT5CYP2D6 | |
| SCHEMBL5456587 | 0.90 | CDC42 (0.70) | CDC42GAACASP6PRMT5CYP2D6 | |
| SCHEMBL5459705 | 0.84 | CDC42 (0.62) | CDC42GAACASP6PRMT5CYP2D6 | |
| SCHEMBL5461141 | 0.84 | CDC42 (0.76) | CDC42GAACASP6PRMT5CYP2D6 | |
| SCHEMBL5448104 | 0.83 | GAA (0.65) | CDC42GAACASP6PRMT5CYP2D6 | |
| SCHEMBL5454096 | 0.82 | CDC42 (0.50) | CDC42GAACASP6DHODH | |
| SCHEMBL4196072 | 0.80 | CYP2D6 (0.67) | CDC42GAACASP6PRMT5CYP2D6 | |
| SCHEMBL14361488 | 0.80 | CDC42 (0.61) | CDC42GAACASP6PRMT5CYP2D6 | |
| SCHEMBL5447038 | 0.80 | BRD3 (0.63) | CDC42GAACASP6PRMT5CYP2D6 | |
| SCHEMBL4187019 | 0.80 | GAA (0.72) | CDC42GAACASP6PRMT5CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | CDC42 1241/4885GAA 1417/4885CASP6 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.